View ValuationMedical Developments International 将来の成長Future 基準チェック /36Medical Developments International利益と収益がそれぞれ年間80%と10.4%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に4.1% 80%なると予測されています。主要情報80.0%収益成長率79.97%EPS成長率Pharmaceuticals 収益成長14.5%収益成長率10.4%将来の株主資本利益率4.06%アナリストカバレッジLow最終更新日22 May 2026今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Feb 16Medical Developments International Limited to Report First Half, 2026 Results on Feb 19, 2026Medical Developments International Limited announced that they will report first half, 2026 results on Feb 19, 2026お知らせ • Sep 22Medical Developments International Limited Announces Board ChangesMedical Developments International Limited announced the appointment of Mr. Mark Fladrich as Chair of the Board, effective 1 December 2025. Mr. Fladrich succeeds Mr. Gordon Naylor, who will step down as Chair and resign from the Board on the same date. Mr. Fladrich joined the Board in April 2025 and brings over 30 years of experience in the international pharmaceutical industry. His career includes senior leadership roles at global companies, where he has demonstrated exceptional commercial, strategic, and operational expertise across a broad range of therapeutic areas, including pain management. He currently also serves as Chair of QBiotics, an Australian unlisted public life sciences company focused on oncology and wound healing therapies. During his executive career, Mr. Fladrich was Chief Commercial Officer at Grunenthal, a privately owned German company specialising in pain management. In that role, he led the global commercial organisation, expanded the company's presence into the US, and relaunched a key pain treatment in that market. Prior to joining Grunenthal, Mr. Fladrich spent 23 years at AstraZeneca. Mr. Fladrich held several senior roles there including Vice President Global Strategic Marketing, Country President roles in Germany, Australia and New Zealand and Regional Head of Southern and Western Europe. Mr. Naylor has served as a Director and Chair of the Board since October 2020. He currently holds several other governance roles, including Chair of the Board Audit and Risk Committee at Orica Limited and Chair-elect of CSL Seqirus which is anticipated to be demerged from CSL later this financial year. Mr. Naylor remains a shareholder of MVP, holding approximately 1% of MVP's issued stock. As part of its governance considerations, the Board has also taken the opportunity to create a Deputy Chair role and has appointed the Chair of Audit and Risk Committee, Mr. Paul Townsend, to that position. Mr. Townsend joined the Board in May 2025 and has brought a wealth of knowledge to MVP given his distinguished CFO career spanning multiple sectors.お知らせ • Aug 20Medical Developments International Limited, Annual General Meeting, Oct 10, 2025Medical Developments International Limited, Annual General Meeting, Oct 10, 2025.お知らせ • Aug 13Medical Developments International Limited to Report Fiscal Year 2025 Results on Aug 21, 2025Medical Developments International Limited announced that they will report fiscal year 2025 results on Aug 21, 2025お知らせ • Feb 12Medical Developments International Limited to Report First Half, 2025 Results on Feb 20, 2025Medical Developments International Limited announced that they will report first half, 2025 results on Feb 20, 2025お知らせ • Nov 14Medical Developments International Limited Announces Resignation of Mary Sontrop from the Board, Effective December 20, 2024On November 14, 2024, Medical Developments International Limited announced the resignation of Mary Sontrop from the board effective from December 20, 2024. The company announced, Mary has made a significant contribution to the Company over her 4-year tenure on the Board.お知らせ • Sep 03Medical Developments International Limited, Annual General Meeting, Oct 24, 2024Medical Developments International Limited, Annual General Meeting, Oct 24, 2024.お知らせ • Jul 28Medical Developments International Limited has filed a Follow-on Equity Offering in the amount of AUD 10.012039 million.Medical Developments International Limited has filed a Follow-on Equity Offering in the amount of AUD 10.012039 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 14,605,263 Price\Range: AUD 0.38 Discount Per Security: AUD 0.019 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 11,742,207 Price\Range: AUD 0.38 Discount Per Security: AUD 0.019 Transaction Features: Rights Offering; Subsequent Direct Listingお知らせ • Jul 12Medical Developments International Limited to Report Q4, 2024 Results on Aug 26, 2024Medical Developments International Limited announced that they will report Q4, 2024 results on Aug 26, 2024お知らせ • Feb 28Medical Developments International Limited to Report First Half, 2024 Results on Feb 29, 2024Medical Developments International Limited announced that they will report first half, 2024 results on Feb 29, 2024お知らせ • Sep 11Medical Developments International Limited, Annual General Meeting, Oct 27, 2023Medical Developments International Limited, Annual General Meeting, Oct 27, 2023. Agenda: To consider the election of Directors.お知らせ • Aug 31Medical Developments International Limited Appoints Russell Basser to the Board Effective 1 September 2023Medical Developments International Limited announced the appointment of Dr Russell Basser to the Board effective 1 September 2023. Dr Basser is a qualified physician, with over 30 years of international medical and biopharmaceutical experience. Dr Basser's worked as a medical oncologist in Melbourne prior to joining CSL in 2001. During his 21 years at CSL, he held multiple global executive roles, including Head of Global Clinical Development, Chief Medical Officer and Senior VP of Research and Development for CSL Seqirus. Dr Basser has substantial expertise in international drug and vaccine development and spent several years based in the USA. Dr Basser currently serves as a non-executive director on the Boards of Starpharma Holdings Limited andDoherty Clinical Trials. He has previously served on the Board of the ANZ Breast Cancer Trials Group and the Hadassah Australia Medical Research Collaboration.お知らせ • Aug 15Medical Developments International Limited to Report Fiscal Year 2023 Results on Aug 31, 2023Medical Developments International Limited announced that they will report fiscal year 2023 results on Aug 31, 2023お知らせ • Feb 06Medical Developments International Limited to Report First Half, 2023 Results on Feb 24, 2023Medical Developments International Limited announced that they will report first half, 2023 results on Feb 24, 2023お知らせ • Jan 19Medical Developments International Limited Discontinues China Clinical TrialsMedical Developments International Limited announced that it has discontinued the preparation of clinical trials for Penthrox in China. This follows extended delays to the anticipated timeline for clinical trial outcomes and consequently the commercial launch of Penthrox in the market, primarily due to the challenging regulatory environment and COVID restrictions.業績と収益の成長予測OTCPK:MDDV.F - アナリストの将来予測と過去の財務データ ( )AUD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数6/30/20285344526/30/20274710126/30/202643-112212/31/202541001N/A9/30/202540000N/A6/30/2025390-10N/A3/31/202539-15-4-3N/A12/31/202438-30-7-5N/A9/30/202436-35-11-8N/A6/30/202433-41-14-11N/A3/31/202433-30-17-12N/A12/31/202334-19-20-14N/A9/30/202333-12-22-15N/A6/30/202332-6-24-16N/A3/31/202329-4-22-16N/A12/31/202226-2-20-15N/A9/30/202224-7-18-13N/A6/30/202222-12-16-11N/A3/31/202222-16-17-10N/A12/31/202122-19-17-10N/A9/30/202124-16-16-9N/A6/30/202125-13-15-9N/A3/31/202125-7-14-8N/A12/31/202024-1-13-6N/A9/30/2020230-11-3N/A6/30/2020230-90N/A3/31/2020221-81N/A12/31/2019221-81N/A9/30/2019221N/A11N/A6/30/2019211N/A21N/A3/31/2019201N/A22N/A12/31/2018190N/A23N/A9/30/2018180N/A12N/A6/30/2018170N/A2N/A3/31/2018181N/A2N/A12/31/2017182N/A3N/A9/30/2017182N/A3N/A6/30/2017182N/A4N/A3/31/2017182N/A4N/A12/31/2016182N/A4N/A9/30/2016172N/A8N/A6/30/2016152N/A12N/A3/31/2016141N/A12N/A12/31/2015121N/A13N/A9/30/2015121N/A8N/A6/30/2015122N/A3N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: MDDV.Fは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 3.5% ) よりも高い成長率であると考えられます。収益対市場: MDDV.F今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: MDDV.F今後 3 年以内に収益を上げることが予想されます。収益対市場: MDDV.Fの収益 ( 10.4% ) US市場 ( 11.7% ) よりも低い成長が予測されています。高い収益成長: MDDV.Fの収益 ( 10.4% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: MDDV.Fの 自己資本利益率 は、3年後には低くなると予測されています ( 4.1 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 09:24終値2026/05/06 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Medical Developments International Limited 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Martyn JacobsBell PotterMartyn JacobsCanaccord GenuityDan HurrenMST Financial Services Pty Limited
お知らせ • Feb 16Medical Developments International Limited to Report First Half, 2026 Results on Feb 19, 2026Medical Developments International Limited announced that they will report first half, 2026 results on Feb 19, 2026
お知らせ • Sep 22Medical Developments International Limited Announces Board ChangesMedical Developments International Limited announced the appointment of Mr. Mark Fladrich as Chair of the Board, effective 1 December 2025. Mr. Fladrich succeeds Mr. Gordon Naylor, who will step down as Chair and resign from the Board on the same date. Mr. Fladrich joined the Board in April 2025 and brings over 30 years of experience in the international pharmaceutical industry. His career includes senior leadership roles at global companies, where he has demonstrated exceptional commercial, strategic, and operational expertise across a broad range of therapeutic areas, including pain management. He currently also serves as Chair of QBiotics, an Australian unlisted public life sciences company focused on oncology and wound healing therapies. During his executive career, Mr. Fladrich was Chief Commercial Officer at Grunenthal, a privately owned German company specialising in pain management. In that role, he led the global commercial organisation, expanded the company's presence into the US, and relaunched a key pain treatment in that market. Prior to joining Grunenthal, Mr. Fladrich spent 23 years at AstraZeneca. Mr. Fladrich held several senior roles there including Vice President Global Strategic Marketing, Country President roles in Germany, Australia and New Zealand and Regional Head of Southern and Western Europe. Mr. Naylor has served as a Director and Chair of the Board since October 2020. He currently holds several other governance roles, including Chair of the Board Audit and Risk Committee at Orica Limited and Chair-elect of CSL Seqirus which is anticipated to be demerged from CSL later this financial year. Mr. Naylor remains a shareholder of MVP, holding approximately 1% of MVP's issued stock. As part of its governance considerations, the Board has also taken the opportunity to create a Deputy Chair role and has appointed the Chair of Audit and Risk Committee, Mr. Paul Townsend, to that position. Mr. Townsend joined the Board in May 2025 and has brought a wealth of knowledge to MVP given his distinguished CFO career spanning multiple sectors.
お知らせ • Aug 20Medical Developments International Limited, Annual General Meeting, Oct 10, 2025Medical Developments International Limited, Annual General Meeting, Oct 10, 2025.
お知らせ • Aug 13Medical Developments International Limited to Report Fiscal Year 2025 Results on Aug 21, 2025Medical Developments International Limited announced that they will report fiscal year 2025 results on Aug 21, 2025
お知らせ • Feb 12Medical Developments International Limited to Report First Half, 2025 Results on Feb 20, 2025Medical Developments International Limited announced that they will report first half, 2025 results on Feb 20, 2025
お知らせ • Nov 14Medical Developments International Limited Announces Resignation of Mary Sontrop from the Board, Effective December 20, 2024On November 14, 2024, Medical Developments International Limited announced the resignation of Mary Sontrop from the board effective from December 20, 2024. The company announced, Mary has made a significant contribution to the Company over her 4-year tenure on the Board.
お知らせ • Sep 03Medical Developments International Limited, Annual General Meeting, Oct 24, 2024Medical Developments International Limited, Annual General Meeting, Oct 24, 2024.
お知らせ • Jul 28Medical Developments International Limited has filed a Follow-on Equity Offering in the amount of AUD 10.012039 million.Medical Developments International Limited has filed a Follow-on Equity Offering in the amount of AUD 10.012039 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 14,605,263 Price\Range: AUD 0.38 Discount Per Security: AUD 0.019 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 11,742,207 Price\Range: AUD 0.38 Discount Per Security: AUD 0.019 Transaction Features: Rights Offering; Subsequent Direct Listing
お知らせ • Jul 12Medical Developments International Limited to Report Q4, 2024 Results on Aug 26, 2024Medical Developments International Limited announced that they will report Q4, 2024 results on Aug 26, 2024
お知らせ • Feb 28Medical Developments International Limited to Report First Half, 2024 Results on Feb 29, 2024Medical Developments International Limited announced that they will report first half, 2024 results on Feb 29, 2024
お知らせ • Sep 11Medical Developments International Limited, Annual General Meeting, Oct 27, 2023Medical Developments International Limited, Annual General Meeting, Oct 27, 2023. Agenda: To consider the election of Directors.
お知らせ • Aug 31Medical Developments International Limited Appoints Russell Basser to the Board Effective 1 September 2023Medical Developments International Limited announced the appointment of Dr Russell Basser to the Board effective 1 September 2023. Dr Basser is a qualified physician, with over 30 years of international medical and biopharmaceutical experience. Dr Basser's worked as a medical oncologist in Melbourne prior to joining CSL in 2001. During his 21 years at CSL, he held multiple global executive roles, including Head of Global Clinical Development, Chief Medical Officer and Senior VP of Research and Development for CSL Seqirus. Dr Basser has substantial expertise in international drug and vaccine development and spent several years based in the USA. Dr Basser currently serves as a non-executive director on the Boards of Starpharma Holdings Limited andDoherty Clinical Trials. He has previously served on the Board of the ANZ Breast Cancer Trials Group and the Hadassah Australia Medical Research Collaboration.
お知らせ • Aug 15Medical Developments International Limited to Report Fiscal Year 2023 Results on Aug 31, 2023Medical Developments International Limited announced that they will report fiscal year 2023 results on Aug 31, 2023
お知らせ • Feb 06Medical Developments International Limited to Report First Half, 2023 Results on Feb 24, 2023Medical Developments International Limited announced that they will report first half, 2023 results on Feb 24, 2023
お知らせ • Jan 19Medical Developments International Limited Discontinues China Clinical TrialsMedical Developments International Limited announced that it has discontinued the preparation of clinical trials for Penthrox in China. This follows extended delays to the anticipated timeline for clinical trial outcomes and consequently the commercial launch of Penthrox in the market, primarily due to the challenging regulatory environment and COVID restrictions.